TABLE 2.
Impact of lgtB mutation (TrL3 LOS) on the induction of complement-mediated killing by bactericidal antibodies in mice
| Vaccine formulation (15% LOS OMVs) | Adjuvant | Titer for indicated bacterial strainc
|
|||
|---|---|---|---|---|---|
| H44/76a (P1.7,16; L3,7) | Cu385b (P1.19,15; L3,7) | M97-250687b (P1;19,15; L3,7) | B16B6b (P1;2; L2) | ||
| L3,7 | AS04 | 4,125 (2,293-7,421) | 2,192 | 11,188 | <100 |
| Al(OH)3 | 2,029 (1,204-3,319) | 1,090 | 1,656 | <100 | |
| TrL3 | AS04 | 3,204 (1,870-5,489) | 4,314 | 4,826 | <100 |
| Al(OH)3 | 828 (477-1,435) | 904 | 871 | <100 | |
a
Geometric mean titers for 50% killing (calculated on 30 individual sera) and confidence intervals at 95%.
b
SBA titers of pooled sera (n = 30).
c
PorA and LOS immunotypes are in parentheses following the strain names.